Comparison between empirical prokinetics, Helicobacter test-and-treat and empirical endoscopy in primary-care patients presenting with dyspepsia: A one-year study by Lam, KF et al.
Title
Comparison between empirical prokinetics, Helicobacter test-
and-treat and empirical endoscopy in primary-care patients
presenting with dyspepsia: A one-year study
Author(s)
Hu, WHC; Lam, SK; Lam, CLK; Wong, WM; Lam, KF; Lai, KC;
Wong, YH; Wong, BCY; Chan, AOO; Chan, CK; Leung, GM; Hui,
WM
Citation World Journal Of Gastroenterology, 2006, v. 12 n. 31, p. 5010-5016
Issued Date 2006
URL http://hdl.handle.net/10722/86728
Rights Creative Commons: Attribution 3.0 Hong Kong License
PO Box 2345, Beijing 100023, China                                                                                                                  World J Gastroenterol  2006 August 21; 12(31): 5010-5016
www.wjgnet.com                                                                                                                                          World Journal of Gastroenterology  ISSN 1007-9327
wjg@wjgnet.com                                                                                                                                                                       © 2006 The WJG Press. All rights reserved.
Comparison between empirical prokinetics, Helicobacter test-
and-treat and empirical endoscopy in primary-care patients 
presenting with dyspepsia: A one-year study
Wayne HC Hu, SK Lam, Cindy LK Lam, WM Wong, KF Lam, KC Lai, YH Wong, Benjamin CY Wong, 
Annie OO Chan, CK Chan, Gabriel M Leung, WM Hui
Wayne HC Hu, SK Lam, Cindy LK Lam, WM Wong, KC Lai, 
YH Wong, Benjamin CY Wong, Annie OO Chan, CK Chan, 
WM Hui, Department of Medicine, University of Hong Kong, 
Hong Kong, China
KF Lam, Department of Statistics and Actuarial Science, 
University of Hong Kong, Hong Kong, China
Gabriel M Leung, Department of Community Medicine, 
University of Hong Kong, Hong Kong, China
Supported by the peptic ulcer research fund and the Simon To 
fund for swallowing and functional gastrointestinal disorders
Correspondence to: Dr. Wayne Hu, University Department of 
Medicine, Queen Mary Hospital, Pokfulam Road, Hong Kong, 
China. hchu@hku.hk
Telephone: +852-28554742   
Received: 2005-08-24          Accepted: 2005-10-26
Abstract
AIM: To investigate the optimal strategy to treat 
dyspeptic patients in primary care.
METHODS: Dyspeptic patients presenting to primary 
care outpatient clinics were randomly assigned to: 
(1) empirical endoscopy, (2) H pylori  test-and-treat, 
and (3) empirical prokinetic treatment with cisapride. 
Early endoscopy was arranged if patients remained 
symptomatic after 2 wk. Symptom severity, quality-of-
life (SF-36) as well as patient preference and satisfaction 
were assessed. All patients underwent endoscopy by wk 
6. Patients were followed up for one year.
RESULTS: Two hundred and thirty four patients were 
recruited (163 female, mean age 49). 46% were H pylori  
positive. 26% of H pylori  tested and 25% of empirical 
prokinetic patients showed no improvement at wk 2 
follow-up and needed early endoscopy. 15% of patients 
receiving empirical cisapride responded well to treatment 
but peptic ulcer was the final diagnosis. Symptom 
resolution and quality-of-life were similar among the 
groups. Costs for the three strategies were HK$4343, 
$1771 and $1750 per patient. 66% of the patients 
preferred to have early endoscopy.
CONCLUSION: The three strategies are equally 
effective. Empirical prokinetic treatment was the least 
expensive but peptic ulcers may be missed with this 
treatment. The H pylori  test-and-treat was the most 
cost-effective option.
© 2006 The WJG Press. All rights reserved.
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INTRODUCTION
Dyspepsia, defined as pain or discomfort centered in 
the upper abdomen, is a common complaint, affecting 
18.5% of  the population in our locality[1]. Underlying 
pathology ranges from functional dyspepsia, peptic ulcer 
to gastrointestinal cancer. Among the various aetiologies, 
functional dyspepsia is the most common diagnosis in 
community-based patients[2]; Up to 79% of  dyspeptic 
patients referred from primary care for open-access 
endoscopy have normal endoscopic findings[3].
Primary care medicine is the first point of  presentation 
for dyspeptic patients. Studies have suggested that 
dyspepsia alone accounts for 20%-70% of  all gastrointes-
tinal consultations with general practitioners; up to one-
third of  these patients may eventually be referred to a 
gastroenterologist[4]. The financial burden for diagnosis 
and treatment of  this common condition is therefore 
great. 
It is unclear how dyspepsia should be investigated 
and treated in primary care settings, but there are several 
common approaches. Empirical endoscopy would 
theoretically be the gold standard in diagnostic accuracy, 
but it is expensive and invasive. Empirical H2 receptor 
antagonist therapy has been extensively studied, but 
has not been shown to have superior cost-benefit over 
empirical endoscopy[5]. In addition, there may be concerns 
that antisecretory treatment may mask symptoms of  
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gastric cancer and lead to a delay in diagnosis. 
Another possible approach is to test for H pylori. The 
close association between H pylori and chronic gastritis that 
accompanies peptic ulcer disease and gastric cancer offers 
an opportunity to screen for organic disease based on the 
presence of  the bacterium.
An alternate approach is empirical prokinetic treatment. 
Studies have demonstrated that cisapride and domperidone 
are beneficial in the treatment of  functional dyspepsia 
over placebo[6-8]. By adopting this approach, the majority 
of  patients with functional dyspepsia could be treated 
appropriately whereas the smaller number of  patients with 
organic dyspepsia may not benefit from this treatment. 
Persistence of  dyspepsia in this group would then lead 
to endoscopy and diagnosis. The small delay in diagnosis 
is not unreasonable since, in real life, many primary care 
doctors would give antacids to dyspeptic patients without 
alarm features and monitor symptoms on follow-up. 
Cisapride has been withdrawn from most markets since 
this study was carried out though related drugs such as 
mosapride are still in use in some countries.
In this study, we investigated empirical endoscopy, 
H pylori test-and-treat, and empirical prokinetic therapy as 
possible diagnostic and treatment strategies in primary-
care patients presenting with dyspepsia.
MATERIALS AND METHODS
Patients aged 18 or older presenting with a primary 
complaint of  previously uninvestigated dyspepsia in four 
government-run primary-care clinics in Hong Kong were 
recruited for the study. Dyspepsia was defined as pain or 
discomfort centered in the upper abdomen[9]. History and 
physical examination were carried out by the primary care 
physician.
Exclusion criteria for this study were current intake 
of  drugs other than antacids for dyspepsia, previous 
peptic ulcer disease, history of  gastric surgery, presence 
of  malignancy within the previous five years, history of  
intake of  aspirin or non-steroidal anti-inflammatory drugs 
in the previous four weeks, presence of  alarm symptoms, 
such as weight loss and gastrointestinal haemorrhage, 
and clinical suspicion of  an organic cause of  dyspepsia. 
In addition, those with a family history of  sudden death, 
history of  palpitations, co-existing intake of  drugs that 
may interact with cisapride and those with an abnormal 
electrocardiogram were excluded.
After obtaining written consent for the trial, a locally-
validated 13-C urea breath test was administered in the 
primary care clinic. The details of  the breath test have 
been described elsewhere, and had a sensitivity and speci-
ficity of  96.5% and 97.7% respectively[10]. The results were 
not disclosed to the patients until after the trial unless the 
patients were randomised into the H pylori test-and-treat 
group.
The patients were subsequently reassessed by one of  
the investigators in the gastroenterological unit of  Queen 
Mary Hospital within 24 h of  initial presentation. Inclusion 
and exclusion criteria were checked and a complete 
physical examination was performed. Electrocardiography 
was also performed on all recruited patients. A previously 
validated Chinese (Hong Kong) version of  the SF-36 
health survey[11], as well as a validated twelve-item 
dyspepsia symptom severity score[12] were administered. 
Patients were then randomised using a computer-generated 
sequence into one of  three investigation and treatment 
groups as detailed below.
This study was approved by the research and ethics 
committee, faculty of  medicine, the University of  Hong 
Kong.
Empirical endoscopy
Patients in this group received endoscopy on the initial 
day attending the gastrointestinal unit. Oesophagogastrod
uodenoscopy was performed by one of  the investigators 
and an endoscopic diagnosis was made. A rapid urease test 
was performed if  the patient had peptic ulcer disease and 
biopsies for histology were taken for gastric ulcers and 
suspicious lesions.
Patients with organic diagnoses were treated accor-
dingly. H pylori eradication therapy was given to those with 
peptic ulcers or erosive gastritis with a positive test for the 
bacterium.
Dyspeptic patients with normal endoscopy or non-
erosive gastritis were considered to have functional 
dyspepsia and were treated with cisapride 5 mg three times 
daily for six weeks.
Helicobacter test-and-treat
Patients who tested positive for H pylori in the 13C 
urease breath test received omeprazole 20 mg twice daily, 
amoxycillin 1 g twice daily, and clarithromycin 500 mg 
twice daily. The local eradication rate for this regimen is 
87.8%[13]. Patients who tested negative for H pylori were 
treated as functional dyspepsia and given cisapride 5 mg 
three times daily for six weeks.
Empirical prokinetics
All patients in this group were given cisapride 5 mg three 
times daily for six weeks regardless of  H pylori positivity 
(Figure 1).
Follow-up
Patients were followed-up at two weeks, six weeks and one 
year after the initial treatment. At follow-up the dyspepsia 
symptom score and SF-36 survey were administered by an 
assessor blinded to the purpose of  the study. Satisfaction 
of  patients in regard to treatment was assessed at wk 6 
using a 4-point Likert scale ranging from dissatisfied to 
very satisfied. Patients were asked whether they prefered 
endoscopy or a trial of  drug treatment as the initial 
approach to their dyspspsia.
If  the symptoms had not improved after two weeks 
of  treatment, endoscopy was performed on group 2 and 
3 patients. Organic pathology discovered at endoscopy 
was treated appropriately. For patients who had empirical 
endoscopy, no further investigation was offered unless 
there was a change in symptoms that raised suspicion of  
organic disease. At the end of  the study, all patients who 
had not previously received endoscopy received an oesoph
agoduodenogastroscopy for a definitive diagnosis.
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Sample size
Sample size was determined using NCSS PASS 2002 (NCSS 
statistical software, Kaysville, Utah, USA). A previous 
study designed to develop dyspepsia severity scores found 
a mean of  20.7 and standard deviation of  3.8 in a local 
population of  dyspeptic patients. The difference in mean 
symptom score between patients who felt better and those 
who did not was 1.2[12]. Based on this result we estimated 
that 70 patients in each of  the three groups would report a 
two-point difference in the mean symptom score between 
one group and the other two with a power of  0.9 and 
significance level of  0.05.
Cost analysis
Cost analysis was performed to examine the economic 
implications of  the three strategies studied. The analysis 
was carried out from the provider’s perspective, given all 
three treatment regimens were ambulatory procedures and 
therefore, assumed to incur similar direct personal, indirect 
and intangible costs to the patients and society generally. 
Costs were calculated according to the gazetted list of  fees 
and charges of  the Hong Kong Hospital Authority and 
hospital formulary costs.
Statistical analysis
The study was analysed according to intention-to-treat. 
Comparison of  baseline dyspepsia scores and quality-
of-life domains was made using one-way ANOVA and 
the Kruskal-Wallis test. Correlation between baseline 
dyspepsia scores and quality-of-life domains was calculated 
using Kendall’s tau. Quality-of-life and dyspepsia symptom 
scores after treatment were compared among the three 
groups using a repeated measures procedure. The null 
hypotheses regarding the main effects of  time points 
and three treatment groups, and the interaction between 
treatment groups and different time points were tested 
using multivariate analysis. Age and sex were also included 
as covariables. Statistical analyses were performed using 
SPSS version 11.0 for windows (SPSS inc., Chicago, 
Illinois, USA).
RESULTS
Patients and demographic characteristics
Six hundred and seventy three patients were screened 
for inclusion in the study, of  which 234 were recruited 
(mean age 49, range 18-79, 163 female). Reasons for 
exclusion included dyspepsia under treatment (257), 
refusal to participate (49), previous investigations for 
dyspepsia (51), non-steroidal antiinflammatory agent 
intake[25], previous gastric surgery or peptic ulcer history[34], 
alarm symptoms[12] abnormal electrocardiogram[6] and 
other malignancy[3]. Baseline characteristics of  the three 
groups of  patients are as tabulated in Table 1. All patients 
completed the six-week treatment assessment period. One 
hundred and eighty one (77.4% overall; 77.1%, 69.2% and 
86.3% in the three respective groups) attended one-year 
follow-up.
Diagnoses
Group one patients had endoscopy before commencing 
treatment and provided the most accurate data of  the 
underlying diagnoses of  dyspepsia. Among the 83 patients 
receiving empirical endoscopy 76 (91.5%) had normal 
findings or non-erosive gastritis, two (2.4%) had gastric 
erosions, four (4.8%) had peptic ulcer and one (1.2%) had 
Dyspepsia
673 screened 
439 excluded
(1) Empirical endoscopy 
           (n  = 83)
(1) H pylori testing 
         (n  = 78)
(1) Empirical cisapride 
            (n  = 73)
Organic 
lesion 
(n  = 7)
No lesion
(n = 76)
 +ve (n = 41)  -ve (n = 37)
   Treat 
accordingly
Cisapride 5 mg
      t.d.s
Omeprazole 20 mg b.d.
Amoxycillin 1g b.d. 
Clarithromycin 500 mg b.d.
Cisapride 5 mg
          t.d.s
Cisapride 5 mg
t.d.s
Wk 2
Continue
treatment 
Continue
cisapride
Reassess 
   wk 2
Reassess 
   wk 2
Reassess 
   wk 2
Better
(n = 34)
Pain 
(n = 7)
Better
(n = 30)
Better
(n = 59)
Pain 
(n = 7)
Pain 
(n  = 14)
Continue  Continue 
as appropriate
GastroscopyContinue Continue Continue GastroscopyGastroscopy
Wk 6 Assess 
   Assess+
Gastroscopy
   Assess+
Gastroscopy
   Assess+
Gastroscopy
Assess Yr 1
Assess Assess Assess Assess 
Assess Assess Assess Assess Assess Assess Assess 
Figure 1   Flow chart for the three diagnostic and treatment arms.
Initial
visit
www.wjgnet.com
5012       ISSN 1007-9327     CN 14-1219/ R      World J Gastroenterol       August 21, 2006     Volume 12    Number 31
oesophagitis. Endoscopic findings for the three groups 
are summarised in Table 2. Overall, 46% of  patients were 
H pylori positive.
Fourteen patients (18%) randomised to the H pylori 
test-and-treat group had persistent dyspepsia after two 
weeks of  treatment and needed early endoscopy. None 
of  these patients had organic dyspepsia; two had non-
erosive gastritis and 12 had normal endoscopy. At six 
weeks, three patients with symptom resolution after 
treatment were found to have duodenal ulcers and three 
had gastroduodenal erosions. All of  these patients were 
originally tested to be positive for H pylori and had received 
appropriate eradication therapy, but the ulcer had not 
completely healed by the time of  endoscopy.
Fourteen patients (19%) randomised to empirical 
prokinetic therapy had persistent dyspepsia at two weeks 
follow-up and received early endoscopy. Eleven of  these 
patients had normal endoscopy results or non-erosive 
gastritis, two had gastroduodenal erosions and one had 
a gastric ulcer. More importantly, at the final diagnostic 
endoscopy, two patients were found to have erosions, 
duodenal ulcer and gastric ulcer among those who 
reported symptomatic improvement after treatment. If  
endoscopy was not performed, these organic lesions would 
have likely been missed.
All gastric ulcers detected in this study were benign.
Symptom severity
The mean baseline dyspepsia severity score was 20.3 ± 3.9 
and was not significantly different among the three groups 
studied (Table 1). After six weeks of  treatment, there was a 
decrease in mean symptom score to 15.0 ± 2.9 (5.6, 5.6 and 
4.4 for empirical endoscopy, H pylori testing and empirical 
cisapride, respectively). On one year follow-up, the mean 
dyspepsia score increased to 19.7 ± 7.2. Repeated measures 
analysis showed no significant effect of  treatment group 
on dyspepsia severity. However, patients with organic 
causes of  dyspepsia were less symptomatic than those with 
non-ulcer dyspepsia after one year (Table 3). 
Quality-of-life
The SF-36 health-related quality-of-life scores for the 
various domains are tabulated in Table 4. At baseline, 
there was no difference in quality-of-life between the three 
groups of  patients. There was a significant correlation 
between the severity of  dyspepsia and the BP, GH, MH, 
RE, RP, SF and VT domains, but not the PF domain at 
baseline. At one-year follow-up, there was a general decline 
in quality-of-life when compared to 6 wk follow-up. 
Repeated measures analysis again showed no significant 
effect of  treatment group on quality of  life.
Cost analysis
The calculated six-week investigation and treatment 
costs for empirical endoscopy, H pylori test-and-treat and 
empirical prokinetic therapies are HK$4343, $1771 and 
$1750 per patient, respectively.
Patient satisfaction and preference
Overall, 81% of  patients were either satisfied or very 
satisfied with treatment. There was no significant 
difference in satisfaction among the three diagnostic 
paradigms that were tested (Table 5). 66% of  patients 
preferred to have endoscopy before taking medication; 
the differences in scores were again not significant among 
groups (Table 5).
Side effects of cisapride
No patient given cisapride reported significant palpitations 
or other side effects. All patients were able to complete the 
six-week course of  treatment.
DISCUSSION
Underlying diagnoses of  dyspepsia range from peptic 
ulcer, gastric cancer to functional dyspepsia, and it may 
Table 1  Baseline characteristics
Group           Mean age   Sex (M/F) H pylori      Mean baseline
                                                           positive (%)  dyspepsia score
Empirical 
endoscopy
(n = 83) 52.5 ± 13.2 25/58 37 (44.6%) 20.4 ± 4.0
H pylori 
test-and-treat
(n = 78) 46.5 ± 14.2 24/54 41 (52.6%) 20.8 ± 3.8
Empirical 
prokinetics
(n = 73) 48.6 ± 13.0 22/51 30 (41.1%) 19.6 ± 3.8
P value 0.01a 0.99 0.35 0.16
aP < 0.05.
Table 2  Endoscopic findings in the three groups n  (%)
      Normal     Gastritis/    Gastric   Gastric  Duodenal  Oesop-
                                  duodenitis   erosions   ulcer  ulcer     hagitis
Empirical 
endoscopy 
(n = 83)
  49 (59)  27 (32.5) 2 (2.4) 3 (3.6) 1 (1.2) 1 (1.2)
H pylori 
test-and-
treat (n = 78)
  61 (78.2)  10 (12.8) 4 (5.1) 0 3 (3.9) 0
Empirical 
prokinetics 
(n = 73)
  46 (63.0)  17 (23.3) 4 (5.5) 3 (4.1) 3 (4.1) 0
Table 3  Mean dyspepsia symptom score by initial diagnosis
                                           Baseline        Wk 6      Yr 1
Non-ulcer dyspepsia (n = 210)1 20.3 15.0 20.1
Duodenal Ulcer (n = 7) 19.1 13.0 13.7
Gastric ulcer (n = 6) 23.3 18.7 14.4
Oesopohagitis (n = 1) 17.0 12.0 17.0
Gastric erosion (n = 10) 29.0 15.0 12.0
All causes organic dyspepsia (n = 24)1 20.5 15.1 16.3
1P = 0.045 between the two groups with age and sex as covariables.
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be difficult to determine cause without investigation. Age, 
symptom assessment and even the presence of  alarm 
symptoms appear to be poor predictors of  underlying 
pathology[14]. However, despite the prevalence and 
potential high economic cost of  this condition, the optimal 
strategy to manage dyspepsia in primary care practice 
remains unclear[15]. 
Community-based studies have generally indicated 
that peptic ulcer and cancer are uncommon causes of  
dyspepsia[2], accounting for only 20% of  patients referred 
to open-access endoscopy[3]. Therefore, it is reasonable 
that any investigative and treatment strategy should be 
effective in functional dyspepsia, representing the bulk 
of  patients. The optimal approach to investigation and 
treatment would aim to: (1) provide the most efficacious 
and cost-effective treatment for functional dyspepsia, (2) 
allow for prompt treatment of  patients with peptic ulcer, 
with H pylori eradication, if  appropriate, (3) correctly 
diagnose malignant lesions so that definitive treatment 
can be given and (4) to avoid unnecessary treatment for 
patients with functional dyspepsia.
Several treatments have generally been shown to 
be better than placebo in the treatment of  functional 
dyspepsia. Meta-analysis studies have estimated a 20% gain 
of  H2 antagonist treatment against placebo[16], but there 
may not be global improvement in symptoms[17]. Proton 
pump inhibitors may benefit dyspeptic patients with co-
existing reflux[18]; a study reported 10% therapeutic gain 
over placebo treatment but efficacy seems to be limited 
to patients with ulcer-like symptoms[19]. Cisapride has also 
been extensively evaluated in studies, though many studies 
had methodological deficiencies[20]. Meta-analyses have 
generally found a therapeutic gain of  36%-39% when 
compared to placebo[16,21] but publication bias may have 
contributed to these results. H pylori eradication is likewise 
controversial, with some studies showing a long-term 
benefit[22], and others showing no benefit[23].
Va r ious op t ions have been sug g es ted in the 
investigation and treatment of  patients presenting with 
dyspepsia. The American Gastroenterological Association 
has suggested that patients over the age of  45 years 
or those with alarm features should have empirical 
endoscopy[24]. For younger patients without alarm 
symptoms, there may be several options: (1) empirical 
medical therapy (antisecretory drugs or prokinetics) 
with investigation for therapeutic failures, (2) immediate 
diagnosis with endoscopy, (3) testing for H pylori and 
studying positive subjects, and (4) testing for H pylori and 
treating positive cases with eradication[24]. An Asian Pacific 
guideline also suggested a trial of  antisecretory drugs or 
prokinetics for 2-4 wk[25]. Among the alternatives, empirical 
prokinetic treatment has not been evaluated in previous 
studies. 
Bytzer randomised 414 patients into groups receiving 
empirical endoscopy or ranitidine[5]. Empirical treatment 
was associated with higher costs of  ulcer drug use and a 
greater number of  sick days. It was also notable that 33% 
of  patients had organic causes of  dyspepsia, compared 
to 8% in the present study. Another study comparing 
H pylori test-and-treat with endoscopy found greater 
patient satisfaction with endoscopy but comparable 
symptoms and sick leave days between the two groups[26]. 
Comparative costs depend on individual centres. An 
American study reported similar costs between H pylori 
testing and empirical endoscopy[27] whereas another 
claimed lower costs for H pylori eradication[28]. A decision 
analysis supported a trial of  proton pump inhibitor before 
endoscopy or test-and-treat[29]. Test and endoscopy in 
primary care has been shown to increase endoscopy rates 
without benefit in symptom relief  or quality of  life[30]. It is 
of  note, however, that proton pump inhibitors may not be 
as efficacious in Asian populations; a paper using the same 
outcome instruments as the present study failed to show 
any benefit of  four-week lansoperazole treatment over 
placebo in patients with functional dyspepsia[31].
Most of  the studies comparing different diagnostic 
strategies concentrated on cost. Less data is available 
concerning symptom resolution and quality of  life. Many 
dyspeptic patients presenting for medical care have a 
fear of  serious disease and malignancy[32]. In addition 
Table 4  Median SF-36 quality-of-life scores for the three diagnostic and treatment groups (wk 0/ wk 6/ one year). Transformed 
scores out of 100
                             BP   GH         MH                PF         RE               RP      SF             VT
All groups 63/84/51 40/47/42 72/72/60 95/95/85 100/100/67 50/100/75 88/88/75 45/50/50
Empirical endoscopy 62/84/51 50/52/50 72/72/60 95/95/85 100/100/67 75/100/75 75/100/75 50/45/50
H pylori test-and-treat 62/84/51 40/45/36 68/72/60 95/95 80 67/100/33 50/100/75 75/88/63 45/45/45
Empirical Prokinetics 72/84/52 39/49/45 76/72/64 95/95/85 100/100/67 50/100/75 88/88/75 45/50/50
Table 5  Patient satisfaction and preference among the three 
diagnostic and treatment groups n  (%)
         Very       Satisfied    Neutral   Dissatisfied  Prefer initial
                      satisfied         endoscopy
Empirical 
endoscopy
7 (8.4) 59 (71) 14 (17) 3 (3.6) 63 (75.9)
(n = 83)
H pylori 
test-and-treat
6 (7.7) 53 (67.9) 14 (17.9) 5 (6.4) 48 (61.5)
(n = 78)
Empirical 
prokinetics
6 (8.2) 56 (76.7)   8 (11.0) 3 (4.1) 43 (59.0)
(n = 73)
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BP: bodily pain; GH: general health; MH: mental health; PF: physical functioning; RE: role-emotional; RP: role-physical; SF: social functioning; VT: vitality.
they are more anxious than non-presenters with similar 
complaints[1]. It is possible that a completely normal 
endoscopy may relieve some of  the anxiety. Indeed a study 
on barium meal in dyspeptic patients who were referred 
from general practice showed that the examination 
increased management confidence and allayed patients’ 
anxiety[33]. In this study, however, we failed to show any 
significant difference in symptom relief  among the three 
groups, indicating that the comforting effect of  a negative 
endoscopy may not be an important factor in the cure of  
functional dyspepsia.
We have calculated the cost of  treatment and empirical 
endoscopy is most costly, followed by H pylori test-and-
treat and the lowest cost was for empirical prokinetics. 
The high cost for empirical endoscopy in the present 
study is related to the relatively low rates of  endoscopy 
for patients randomised to the other groups. In the 
H pylori test-and-treat and empirical cisapride groups, 18% 
and 19% of  patients respectively had persistent dyspepsia 
after two weeks of  treatment and needed early endoscopy. 
In Bytzer’s study, 136 out of  206 patients randomised 
to empirical H2 blocker therapy had therapeutic failure 
and required endoscopy[5]. The difference may be due to 
differences in length of  follow-up and also the lower rate 
of  organic pathology in our study. In our population with 
dyspepsia, 8.5% had organic causes (empirical endoscopy 
group), compared with 33% prevalence of  organic 
dyspepsia reported by Bytzer. The overall rate of  organic 
dyspepsia is also lower than the rate in our previous 
study on open-access endoscopy, where 21% had organic 
pathology[3]. The difference probably reflects differences 
in referral patterns, with family physicians referring more 
severe cases of  dyspepsia for immediate endoscopy in the 
previous study.
We observed a high relapse rate of  dyspepsia generally, 
with the mean dyspepsia severity score returning to the 
initial level on one-year follow-up. This is due to non-
ulcer/functional dyspepsia being the predominant 
diagnosis in 92% of  patients. Functional dyspepsia is a 
chronic disease that persists in patients; a study reported 
that 74% of  dyspeptic patients are still symptomatic two 
years after the initial diagnosis[34]. In contrast, the few 
patients with peptic ulcer in this study tended to remain 
asymptomatic after the ulcer has healed and these patients 
in fact have a better prognosis as far as symptom relapse is 
concerned.
Both empirical endoscopy and H pylori testing appeared 
to be safe options with similar patient satisfaction. All 
patients with organic dyspepsia were tested to be positive 
for H pylori and had appropriate eradication therapy. 
However, the main drawback in the study was the absence 
of  malignancy; it was not possible to predict whether 
gastric cancers would have been missed by any approach. 
Although rare in younger patients, gastric cancers may 
present without sinister symptoms. A Canadian study 
reported a prevalence of  1.05 per thousand patients 
under 45 years presenting with dyspepsia without alarm 
symptoms[35]. We may expect higher numbers in Asia, 
with a higher population prevalence of  gastric cancer. 
The possibility of  missing or delay in diagnosis of  gastric 
malignancies needs to be considered in empirical treatment 
approaches.
Since all patients with duodenal or gastric ulcer were 
positive for H pylori, another approach may be performing 
endoscopy only on those with a positive 13C urea breath 
test. Such an approach may prevent 54% of  endoscopies. 
However, 60% of  the patients with gastric erosions were 
negative for H pylori; inappropriate treatment of  these 
patients may potentially lead to progression into ulcer 
disease.
There is limited data on empirical prokinetic treatment. 
Because of  association with cardial arrhythmia, the drug 
has been withdrawn in most markets. However, related 
drugs, such as mosapride, are still used in some countries 
and this study may throw light on the effectiveness of  
other prokinetic agents. In the present study we found 
this strategy to be associated with the lowest cost but with 
similar outcome regarding symptomatic improvement. 
However, interestingly, although prokinetic treatment was 
not targeted for the treatment of  peptic ulcers, six patients 
(2 gastric ulcer, 2 duodenal ulcer, 2 gastric erosions) 
reported symptomatic improvement after cisapride alone 
and would not have received definitive therapy. Because of  
the dangers of  misdiagnosing patients with peptic ulcers, 
empirical cisapride therapy could not be recommended. 
Despite concerns over potential QT interval prolongation 
and ventricular arrhythmia, a relatively low dose of  5 mg 
three times daily was not associated with any adverse event 
in our sample of  patients.
In conclusion, most patients presenting to primary 
care physicians with dyspepsia appear to have non-ulcer 
dyspepsia, which is associated with a high one-year relapse 
rate. Empirical endoscopy, H pylori test-and-treat and 
empirical prokinetic treatments appear to have similar 
efficacy in improvement of  dyspepsia and quality-of-
life. Empirical prokinetics may result in organic lesions 
being missed in diagnosis. Most patients preferred having 
endoscopy first, if  given the choice, but this is the most 
expensive option. H pylori test-and-treat is the most cost-
effective safe treatment.
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